LCM
LOGC

Laurion Capital Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Laurion Capital Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,000
Closed -$156K – 1408
2018
Q4 		$156K Buy
+15,000
New +$181K ﹤0.01% 987

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Laurion Capital Management's LOGC Position: Q1 2019 in Review

Laurion Capital Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2019, closing a stake of 15,000 shares — an estimated $156K sold.

Laurion Capital Management first reported a position in LOGC in Q4 2018 and held it in 1 quarter. The position peaked at $156K in Q4 2018. 33 funds tracked by Wall St. Rank hold LOGC as of Q1 2019.

  • Laurion Capital Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Laurion Capital Management sold 15,000 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $156K.
  • Laurion Capital Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Laurion Capital Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $156K in Q4 2018.
  • 33 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Laurion Capital Management's 13F filing for Q1 2019, filed 8 May 2019.